A proof-of-concept phase I clinical trial demonstrates that targeting interleukin (IL)-23 with an antibody that binds to the p19 subunit leads to clinical improvement of disease in patients with moderate to severe psoriasis.
- Tamara Kopp
- Elisabeth Riedl
- Sauzanne Khalilieh